Global Healthcare

European Obesity Market on Track to Show Drug, Device Gains

1 Mins read

The FDA put a slight dent in forecasts for obesity drugs, with a negative view (and decisions) in 2010 that it now seems to be backing away from.

Having forecasted the obesity market earlier this year and having taken a position that the FDA might well revisit its negative decisions on Contrave, Lorcaserin and Qnexa (especially if additional trial data is submitted to address specific concerns), we still hold that there will be substantial upside in obesity drugs (and devices) over the coming decade.

The FDA put a slight dent in forecasts for obesity drugs, with a negative view (and decisions) in 2010 that it now seems to be backing away from.

Having forecasted the obesity market earlier this year and having taken a position that the FDA might well revisit its negative decisions on Contrave, Lorcaserin and Qnexa (especially if additional trial data is submitted to address specific concerns), we still hold that there will be substantial upside in obesity drugs (and devices) over the coming decade.

This is especially true for Europe which, at least in principle, is unaffected by FDA decisions. Below is our forecast of the obesity products market, by specific drug and device types, for Europe through 2019 (sales in $millions). 

 

Eurobesity

 

Source: MedMarket Diligence, LLC; Report S835.

 

Posted via email from medmarket’s posterous

     

Avatar
183 posts

About author
I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses. Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.
Articles
Related posts
Global HealthcarePolicy & Law

Do HMOs Deserve A Bad Reputation? The Truth Of Managed Healthcare

3 Mins read
Have you ever heard people say that HMO health insurance is no good? It’s no secret that HMOs have a bad reputation,…
Global Healthcare

5 Serious Health Problems Caused By Poor Cleanliness

3 Mins read
There are a lot of things that we need to do to stay healthy. We need to eat right, get regular physicals…
eHealthGlobal HealthcareHealth care

How IoT Healthcare Devices Like Wearable Devices Disrupt Healthcare

3 Mins read
We have previously written a number of blog articles about the utilization of artificial intelligence and data analytics in healthcare. Most of…